Drug Profile
Research programme: TransKingdom RNA interference therapeutics - Adhera Therapeutics
Alternative Names: CEQ 400; CEQ 600; CEQ 700; CEQ-501; CEQ-626; CEQ608; CEQ609; CEQ621; CEQ631; CEQ632; tk RNAi; tkRNAi therapeutic targeting beta-catenin (CTNNB1) - Adhera Therapeutics; TransKingdom RNA interferenceLatest Information Update: 03 May 2019
Price :
$50
*
At a glance
- Originator Cequent Pharmaceuticals
- Developer Adhera Therapeutics
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Human papillomavirus infections; Inflammatory bowel diseases